❌

Normal view

Mixture-of-Experts Meets In-Context Reinforcement Learning

arXiv:2506.05426v2 Announce Type: replace-cross Abstract: In-context reinforcement learning (ICRL) has emerged as a promising paradigm for adapting RL agents to downstream tasks through prompt conditioning. However, two notable challenges remain in fully harnessing in-context learning within RL domains: the intrinsic multi-modality of the state-action-reward data and the diverse, heterogeneous nature of decision tasks. To tackle these challenges, we propose T2MIR (Token- and Task-wise MoE for In-context RL), an innovative framework that introduces architectural advances of mixture-of-experts (MoE) into transformer-based decision models. T2MIR substitutes the feedforward layer with two parallel layers: a token-wise MoE that captures distinct semantics of input tokens across multiple modalities, and a task-wise MoE that routes diverse tasks to specialized experts for managing a broad task distribution with alleviated gradient conflicts. To enhance task-wise routing, we introduce a contrastive learning method that maximizes the mutual information between the task and its router representation, enabling more precise capture of task-relevant information. The outputs of two MoE components are concatenated and fed into the next layer. Comprehensive experiments show that T2MIR significantly facilitates in-context learning capacity and outperforms various types of baselines. We bring the potential and promise of MoE to ICRL, offering a simple and scalable architectural enhancement to advance ICRL one step closer toward achievements in language and vision communities. Our code is available at https://github.com/NJU-RL/T2MIR.

RPN1 Is Associated With Immunosuppression in Pan-Cancer and Affects the Malignant Phenotype of Tumor

26 August 2025 at 18:00

FASEB J. 2025 Aug 31;39(16):e70978. doi: 10.1096/fj.202500722RR.

ABSTRACT

Ribophorin 1 (RPN1), a key component of the oligosaccharyltransferase complex, is implicated in tumor progression through glycosylation-mediated pathways, yet its pan-cancer roles remain unexplored. This study presents a comprehensive multi-omics analysis of RPN1 across 33 cancers such as sarcoma (SARC), integrating genomic, transcriptomic, and proteomic data from TCGA, GTEx, and CPTAC. RPN1 was significantly overexpressed in 14 malignancies and correlated with advanced tumor stages and poor prognosis in glioblastoma (GBM), lower-grade glioma, SARC and hepatocellular carcinoma, validated in an independent glioma cohort (n = 151). Genomically, RPN1 amplification linked to homologous recombination deficiency and elevated tumor mutational burden, suggesting a role in genomic instability. Critically, multiplex immunofluorescence demonstrates RPN1 overexpression colocalizes with CD206+ M2 macrophages in tumor microenvironments, while in vitro coculture experiments confirm RPN1-dependent microglial recruitment and M2 polarization. RPN1 expression negatively correlates with CD8+ T cell infiltration and predicts resistance to chemotherapy (GBM, ovarian cancer) and immunotherapy (GBM, esophageal carcinoma), though it associates with PD-1 inhibitor sensitivity in bladder cancer. Functional validation shows RPN1 knockdown suppresses proliferation, migration, and invasion in GBM cells. Pathway enrichment connects RPN1 to endoplasmic reticulum stress, glycosylation, DNA repair, and immune checkpoint regulation. These findings position RPN1 as a multimodal oncogenic driver promoting genomic instability, immunosuppressive microenvironment remodeling, and context-dependent therapeutic vulnerabilities across cancers.

PMID:40857034 | DOI:10.1096/fj.202500722RR

❌